Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

Author： Dillman R.  

Publisher： Springer Publishing Company

ISSN： 1591-8890

Source： Clinical and Experimental Medicine, Vol.6, Iss.1, 2006-03, pp. : 1-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

B‐cell inhibition by cross‐linking CD79b is superior to B‐cell depletion with anti‐CD20 antibodies in treating murine collagen‐induced arthritis

By  

EUROPEAN JOURNAL OF IMMUNOLOGY, Vol. 45, Iss. 3, 2015-03 ,pp. : 705-715

John Wiley & Sons Inc

Access to resources Recommend Favorite

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differential regulation patterns of the anti‐CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 606-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite